<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285866</url>
  </required_header>
  <id_info>
    <org_study_id>GECP 19/02_S-REAL</org_study_id>
    <nct_id>NCT04285866</nct_id>
  </id_info>
  <brief_title>Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.</brief_title>
  <acronym>S-REAL</acronym>
  <official_title>Spanish Real World Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación GECP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación GECP</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-interventional, observational, multicentre, one-arm, non-comparative, and
      retrospective study.

      The study is based on the collection of data about the patients treated with Durvalumab after
      chemoraditherapy in the real world. The patients participating in this non-interventional
      study will not receive treatment in relation to the study. The primary objective is to assess
      affectiveness of durvalumab in patients treated in real-life settings by evaluating
      Progression Free Survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung Cancer represent approximately 13% of total cancer diagnoses worldwide and continues to
      be the leading cause of cancer-related mortality. Stage III represents between 25-30% of
      NSCLC and the majority of them are unresectable. The standard treatment in unresectable
      patients was chemoradiotherapy consurrently if possible.

      The PACIFIC study is a phase III study to evaluate the efficacy and safety of durvalumab as a
      sequential therapy concurrent platinum-based chemotherapy and thoracic RT. The study was
      positive for both primary endpoints progression-free survival and overall survival. After
      that, it was decided to open an early acces programme ti provide acces to durvalumab for
      patients with locally advanced, unresectable NSCLC (stage III) tho have not progressed
      following chemoradiation.

      This observational study is based on the collection of data about the patients treated with
      Durvalumab after chemoraditherapy in the real world.

      The study will include all patients who have participated in the EAP between 1 September 2017
      up to 21 December 2018 and have received at least 1 dose of durvalumab.

      The primary objective is to assess affectiveness of durvalumab in patients treated in
      real-life settings by evaluating Progression Free Survival. Other secondary objectives are:

      To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating
      1-year survival rate, to describe adverse events of special interests, to stimate time and
      sites of disease progression or relapse in metastatic setting, to describe details on
      durvalumab treatment, to describe demographic and clinical characteristics of stage III
      unresectable NSCLC patients treated with Durvalumab, to describe previous chemoradiotherapy
      strategy, to describe the baseline staging status, to further assess subsequent treatments
      pattern at the time of disease progression including duration of therapy and type of therapy,
      and to explore healthcare resource utilization while on durvalumab treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of the first dose of durvalumab received (within the EAP) to the date of disease progression, death, or the end of follow-up, assessed up to 60 months</time_frame>
    <description>To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating PFS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1-year survival rate</measure>
    <time_frame>1 year</time_frame>
    <description>To assess effectiveness of durvalumab in patients treated in real-life settings by evaluating 1-year survival rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe adverse events of special interest (AESIs)</measure>
    <time_frame>From date of the first dose of durvalumab received (within the EAP) to the date of disease progression, death, or the end of follow-up, assessed up to 60 months</time_frame>
    <description>To describe AESIs leading to treatment temporary interruption or permanent discontinuation of durvalumab, or which require interventions of concomitant use of corticosteroids, immunosupressants and/or endocrine therapies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time and site of disease progression or relapse</measure>
    <time_frame>From date of the first dose of durvalumab received to the date of disease progression, assessed up to 60 months</time_frame>
    <description>To estimate time and sites of disease progression or relapse in metastatic setting.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Small Cell Lung Cancer (SCLC)</condition>
  <arm_group>
    <arm_group_label>Durvalumab Group</arm_group_label>
    <description>Patients who have participated in the EAP between 1 September 2017 up to 21 December 2018 and have received at least 1 dose of durvalumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab after chemoradiotherapy</description>
    <arm_group_label>Durvalumab Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who have parcipated in the EAP between 1 September 2017 up to 21 December 2018
        and have received at least 1 dose of durvalumab.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically or cytologically documented diagnosis of NSCLC with
             a locally advanced, or locally recurrent, unresectable (stage III) disease (according
             to American Joint Committee on Cancer [AJCC] lung cancer edition 7 or 8).

          2. Age ≥ 18 years at time of study Entry

          3. Patients must have been treated with chemotherapy and radiotherapy concurrently or
             sequentially and shown no progressive disease following chemoradiation

          4. Patients must have been enrolled in durvalumab EAPs between 1 September 2017 and 21
             December 2018.

          5. Patients must have been treated with at least one dose of durvalumab within the EAP

          6. Alive patients must have signed, dated and IRB/EC-approved written informed consent*
             form in accordance with regulatory and institutional guidelines. This must be obtained
             before the performance of any protocol-related procedures that are not part of normal
             subject care.

        Exclusion Criteria:

          1. Alive patients who do not want to sign and date an IRB/IEC-approved written informed
             consent form.

          2. Patients who were accepted in the EAP, but did not receive treatment.

          3. Patients treated with durvalumab in clinical studies prior to the index date (first
             dose of durvalumab received within the EAP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Noemí Villanueva, MD</last_name>
    </contact>
    <investigator>
      <last_name>Noemí Villanueva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Marta Doménech, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marta Doménech, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Silvia Muñoz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Silvia Muñoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Laia Vilà, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laia Vilà, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Marta López, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marta López, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <state>Gran Canaria</state>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Llàtzar</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Illes Balears</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Xabier Mielgo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xabier Mielgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosa María Villatoro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosa María Villatoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ignacio Gil, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Gil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Donostia</name>
      <address>
        <city>Donostia</city>
        <state>País Vasco</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Alfredo Paredes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alfredo Paredes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ayram Padilla, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ayram Padilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario De La Ribera</name>
      <address>
        <city>Alzira</city>
        <state>Valencia</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Corina Escoín, MD</last_name>
    </contact>
    <investigator>
      <last_name>Corina Escoín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Mª Ángeles Sala, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mª Ángeles Sala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillermo Alonso-Jáudenes, MD</last_name>
    </contact>
    <investigator>
      <last_name>Guillermo Alonso-Jáudenes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Mar Parc de Salut de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Álvaro Taus, MD</last_name>
    </contact>
    <investigator>
      <last_name>Álvaro Taus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>María Teresa Delgado, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Teresa Delgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Enrique Chara, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Enrique Chara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Rosa Álvarez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosa Álvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>Madrid</city>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>María Sereno, MD</last_name>
    </contact>
    <investigator>
      <last_name>María Sereno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario de Ourense</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>José Luis Fírvida, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Luis Fírvida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Lorena Bellido, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lorena Bellido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Segovia</name>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Beatriz Esteban, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beatriz Esteban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruth Álvarez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ruth Álvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politécnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ángel Artal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ángel Artal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced small cell lung cancer</keyword>
  <keyword>SCLC</keyword>
  <keyword>lung cancer</keyword>
  <keyword>durvalumab after chemotherapy</keyword>
  <keyword>real world data</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

